Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1301-1310 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|December 6, 2022
Antibodies to watch in 2023Hélène Kaplon, Silvia Crescioli, Alicia Chenoweth, et al.
Mabs|November 26, 2022
Reduction of therapeutic antibody self-association using yeast-display selections and machine learningEmily K Makowski, Hongwei Chen, Matthew Lambert, et al.
Mabs|July 13, 2022
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopySamantha Phan, Auralee Walmer, Eudean W Shaw, et al.
Mabs|June 22, 2010
EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activityStéphane Olivier, Marine Jacoby, Cédric Brillon, et al.
Mabs|May 25, 2010
5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Martha Anderson, et al.
Mabs|October 22, 2010
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?Rong Deng, Suhasini Iyer, Frank-Peter Theil, et al.
Mabs|October 28, 2010
Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- miceYulia Vugmeyster, David DeFranco, Debra D Pittman, et al.
Mabs|August 3, 2010
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targetsJasmine P Davda, Ryan J Hansen
Mabs|August 19, 2010
Engineering host cell lines to reduce terminal sialylation of secreted antibodiesMichael F Naso, Susan H Tam, Bernard J Scallon, et al.
Mabs|October 16, 2010
Antibody immunosuppressive therapy in solid organ transplant: Part IIDusko Klipa, Nadim Mahmud, Nasimul Ahsan
Pageof 178

Showing results (1301-1310 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|December 6, 2022
Antibodies to watch in 2023Hélène Kaplon, Silvia Crescioli, Alicia Chenoweth, et al.
Mabs|November 26, 2022
Reduction of therapeutic antibody self-association using yeast-display selections and machine learningEmily K Makowski, Hongwei Chen, Matthew Lambert, et al.
Mabs|July 13, 2022
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopySamantha Phan, Auralee Walmer, Eudean W Shaw, et al.
Mabs|June 22, 2010
EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activityStéphane Olivier, Marine Jacoby, Cédric Brillon, et al.
Mabs|May 25, 2010
5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Martha Anderson, et al.
Mabs|October 22, 2010
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?Rong Deng, Suhasini Iyer, Frank-Peter Theil, et al.
Mabs|October 28, 2010
Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- miceYulia Vugmeyster, David DeFranco, Debra D Pittman, et al.
Mabs|August 3, 2010
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targetsJasmine P Davda, Ryan J Hansen
Mabs|August 19, 2010
Engineering host cell lines to reduce terminal sialylation of secreted antibodiesMichael F Naso, Susan H Tam, Bernard J Scallon, et al.
Mabs|October 16, 2010
Antibody immunosuppressive therapy in solid organ transplant: Part IIDusko Klipa, Nadim Mahmud, Nasimul Ahsan
Pageof 178